Inborn error of immunity
MONDO:0003778A disorder in which the immune system is unable to mount an adequate immune response.
Also known as: IEI, inborn errors of immunity, primary immunodeficiency disease, antibody deficiency syndrome, antibody deficiency syndromes, deficiency syndrome, antibody, deficiency syndrome, immunologic, deficiency syndrome, immunological
323 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental drug for rare skin disease fails to reach goal
Disease control TerminatedThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control TerminatedThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental gene therapy aims to fix immune system in rare childhood disease
Disease control TerminatedThis early-phase trial tested a gene therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder that leaves boys unable to fight off bacteria and fungi. The treatment involved taking the patient's own blood stem cells, adding a corrected gene, and infusin…
Phase: PHASE1, PHASE2 • Sponsor: Genethon • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental gene therapy targets rare immune disorder
Disease control TerminatedThis trial tested a gene therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder that leaves boys unable to fight off infections. The treatment involved taking the patient's own blood stem cells, adding a working copy of the faulty gene, and returning …
Phase: PHASE1, PHASE2 • Sponsor: Genethon • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control TerminatedThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug shows promise for rare immune disorder, but study cut short
Disease control TerminatedThis study tested the long-term safety and effectiveness of a drug called CDZ173 in people with APDS/PASLI, a rare genetic condition that causes a weak immune system and swollen lymph nodes. The 37 participants had already taken CDZ173 or a similar drug in a previous study. The t…
Phase: PHASE2, PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control TerminatedThis study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control TerminatedThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Rare skin disease study seeks to understand netherton syndrome
Knowledge-focused TerminatedThis study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Yeast study in rare autoimmune disease terminated early
Knowledge-focused TerminatedThis study aimed to compare the types of Candida yeast found in patients with two forms of autoimmune polyendocrinopathy, a rare condition where the immune system attacks multiple glands. Researchers planned to collect samples from the mouth and urine of 7 participants to see how…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC